endogenous retrovirus group E member 1Genealiases: ERVE1 · HERV-E1 · HERVE1
Q-omics provides the consensus-scored ERVE-1 profile across patient tissues and cancer cell-line models. ERVE-1 expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, ERVE-1 is differentially expressed in 14, with the highest sampling consensus in KIRC. Additionally, ERVE-1 RNA expression shows 16,116 significant protein co-abundance associations, with the highest sampling consensus in PDAC. Together, these results highlight KIRC, and PDAC as cancer lineages where ERVE-1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ERVE-1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ERVE-1 survival associations across molecular data types. ERVE-1 RNA expression shows survival associations in the most cancer types (20), followed by mutation status (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ERVE-1 RNA expression–survival associations across cancer types. High ERVE-1 expression shows unfavorable associations in KIRC, SKCM and PAAD, but favorable associations in LGG, UVM and BLCA. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .002). Together, the overview and detailed table identify KIRC as the clearest survival context for ERVE-1 RNA expression.
This table summarizes ERVE-1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for ERVE-1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ERVE-1 shows lower tumor expression in KIRC, KIRP, LUAD, LUSC, KICH and THCA. The KIRC box plot shows higher ERVE-1 RNA expression in normal versus tumor tissue (log2 FC = −3.083, t-test p < 0.001).
This table shows molecular features associated with ERVE-1 in patient tissues and cancer cell lines. In patient samples, ERVE-1 shows the broadest associations at the RNA and protein expression levels, with PDAC recurring as the lineage with the largest associated feature set.
